The stock of Caribou Biosciences Inc. (NASDAQ:CRBU) decreased by -$0.17 on Tuesday to finish at $6.08, down -2.72 percent. The last five days have seen an average of 1,212,280 shares of common stock traded. 8 times new highs were reached in the current year, with a fall of -$0.20. The average number of shares traded over the last 20 days was 1,231,725, while the average volume over the last 50 days totaled 3,741,070.
CRBU stock dropped -15.44% since last month. On 08/21/23, the company’s shares reached a one-month low of $5.94. The stock touched a high of $13.19 on 07/12/23, after rallying from a low of $3.96 in 52 weeks. The price of CRBU stock has declined by -3.18% or -$0.20 this year, reaching a new high 8 times. Still, the stock price is down -53.90% from the 52-week high.
Insider Transactions
CRBU stock investors should be aware that Caribou Biosciences Inc. (CRBU) stock had its last reported insider trading activity 223 days ago on Jan 19. On Jan 19, Chief Medical Officer Rizvi Syed Ali-aamir sold 5,627 shares at $6.31 each. This transaction resulted in the insider making $35,506. On Oct 06, Fischesser Ryan sold 10,000 shares at a price of US$10.80. After the transaction, the insider now owns 110,366 shares.
Valuation Metrics
Beta for the stock is 1.97. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 37.84, the price-to-book (PB) ratio of 1.38.
Financial Health
For the three months ended June 29, Caribou Biosciences Inc.’s quick ratio was 7.80, while its current ratio was 7.80, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $120.25 million and revenue of $13.85 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CRBU’s return on assets (ROA) during the last 12 months has been -30.30%. There was a -35.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -37.90%.
Earnings Surprise
According to Caribou Biosciences Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $3.76 million, while revenues fell by -11.44% to $3.5 million. It was predicted that Caribou Biosciences Inc.’s quarterly earnings would be -$0.48, but it ended up being -$0.49, beating the consensus by 2.00%. EBITDA was -$34.35 million for the quarter. At the end of Caribou Biosciences Inc.’s most recent quarter ended June 29, its liabilities totaled 80.19 million, while its total debt was $27.23 million. Equity owned by shareholders amounts to $88.28 million.
Technical Picture
Here’s a quick look at Caribou Biosciences Inc.’s (CRBU) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 36.56%, suggesting the stock is Neutral, with a 33.00% historical volatility rate.
The stochastic %K and %D were 17.33% and 21.93% respectively, while the average true range (ATR) was 0.33. Based on the 14-day stochastic reading of 9.41%, the RSI (14) reading is 43.55%. On the 9-day MACD Oscillator, the stock is at -0.03, and the 14-day reading is at -0.23.
Analyst Ratings
In its analyst report released on July 11, 2023, Truist began covering Caribou Biosciences Inc. (NASDAQ: CRBU). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Caribou Biosciences Inc. (CRBU) an Buy rating. CRBU is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 7 others recommend it as a buy.
What is CRBU’s price target for the next 12 months?
The current consensus forecast for the stock is between $19.00 and $37.00, with a median target price of $23.00. In analyzing these forecasts, the average price target given by analysts for Caribou Biosciences Inc. (CRBU) is $24.86.
